Gilead Sciences (GILD) posted better-than-expected fourth-quarter financial results as sales of its hepatitis C drugs exceeded forecasts. Still, the biotech giant gave back after-hour gains as full-year sales forecasts failed to impress.
Gilead also boosted its dividend and almost doubled its share repurchase plan.
At a recent $83, the shares were up 0.4% after earlier climbing more than 2% in after-hour market action. As of todays closing bell, the stock fell 1.6% in todays regular market action to end at $82.71.
Per share profit beat the Streets expectations by 35 cents. Gilead earned $3.32 a share as revenue grew `6% to $8.41 billion during the quarter that ended in December. Analysts surveyed by S&P Capital IQ expected Gilead to earn $2.98 a share on revenue of $8.16 billion.
Sales of hepatitis C drugs Sovaldi and Harvoni totaled $4.9 billion compared to the $4.54 billion expected by the Street.
Gileadincreased its quarterly dividend by 4 cents share, or 9.3% to 47 cents a share. Gilead also announced plans to commence with a $12 billion share repurchase plan after completing its existing $15 billion buyback program authorized in January 2015.
Top 10 Safest Stocks For 2017: Simulations Plus, Inc.(SLP)
Simulations Plus, Inc. designs, develops, and markets drug discovery and development software for mechanistic modeling and simulation. It offers GastroPlus that simulates the absorption, pharmacokinetics, and pharmacodynamics of drugs administered to humans and animals; DDDPlus, which simulates in vitro laboratory experiments that measure the rate of dissolution of the drug and additives in a dosage form; and MembranePlus that simulates laboratory experiments. The company also provides PKPlus, a standalone program that provides the functionality needed by pharmaceutical industry scientists to generate the analyses and outputs to satisfy regulatory agency requirements for NCA and compartmental pharmacokinetics; ADMET Predictor, a chemistry-based computer program that takes molecular structures as inputs and predicts their properties; and MedChem Designer, a molecule drawing program or sketcher that integrates with MedChem Studi o and ADMET Predictor. In addition, it offers MedChem Studio, a tool for data mining and designing new molecules; and KIWI, a cloud-based Web application that organizes, processes, maintains, and communicates the volume of data and results generated by pharmacologists and scientists over the duration of a drug development program. Further, the company provides consulting services ranging from early drug discovery through preclinical and clinical trial data analysis, and reporting to regulatory agencies; and population modeling and simulation contract research services for the pharmaceutical and biotechnology industries. It offers software and services to pharmaceutical, biotechnology, agrochemical, and food companies, as well as regulatory agencies in North America, South America, Europe, Japan, Australia, New Zealand, India, Singapore, and the Peoples Republic of China. Simulations Plus, Inc. was founded in 1996 and is headquartered in Lancaster, California.
- [By Monica Gerson]
Simulations Plus, Inc. (NASDAQ: SLP) is estimated to post its quarterly earnings at $0.07 per share on revenue of $5.00 million.
Posted-In: Earnings scheduleEarnings News Pre-Market Outlook Markets
- [By Benzinga News Desk]
UBS (NYSE: UBS) Q2 EPS $0.83, Revenue $5.45B; Q2 EPS Up ~4% YoY, Revenue Up ~8% YoY
PNC (NYSE: PNC) Q2 EPS $1.82 vs $1.75 est, Revenue $3.79B vs $3.81B est
Simulations Plus (NASDAQ: SLP) Reports Q3 EPS $0.11 vs. Est. $0.12, Rev. $6.01M vs. Est. $6.57M
Top 10 Safest Stocks For 2017: Royal Bank Scotland plc (The)(RBS)
The Royal Bank of Scotland Group plc, together with its subsidiaries, provides banking and financial products and services to personal, commercial, corporate, and institutional customers worldwide. The company operates through Personal & Business Banking (PBB), Commercial & Private Banking (CPB), Corporate & Institutional Banking (CIB), Capital Resolution, Williams & Glyn, and Central Items & Other segments. It offers various traditional retail banking products, including current and savings accounts, residential mortgages, credit cards, loan products, and investment services. The Royal Bank of Scotland Group plc was founded in 1727 and is headquartered in Edinburgh, the United Kingdom.
- [By Jonathan Morgan]
Adidas AG slid 2.9 percent after lowering its profit forecast for 2013. Direct Line Insurance Group Plc lost 2.5 percent as Royal Bank of Scotland Group Plc (RBS) sold a 630 million-pound ($1 billion) stake in the U.K.s biggest car insurer.
- [By Paul R. La Monica]
European banks worse off than 2008? Lamensdorf is concerned about the exposure to bad loans (especially energy company debt) held by big banks such as Royal Bank of Scotland (RBS), Credit Suisse (CS) and Deutsche Bank (DB). He’s shorting all three.
Hot Consumer Service Stocks To Own Right Now: Rackspace Hosting Inc(RAX)
Rackspace Hosting, Inc. operates in the hosting and cloud computing industry. It provides information technology (IT) as a service, managing Web-based IT systems for small and medium-sized businesses, as well as large enterprises worldwide. The company?s service suite includes dedicated hosting comprising customer management portal and other management tools that manage data center, network, hardware devices, and operating system software; and cloud computing that enables customers to provide and manage a pool of computing resources, as well as delivery of computing resources to business when they need them. It offers cloud servers, cloud files, and cloud sites, as well as cloud applications, such as email, collaboration, and file back-ups; and hybrid hosting that provides a combination of dedicated hosting and cloud computing services. The company also offers customer support services. It sells its service suite through direct sales teams, third-party channel partners, an d online ordering. The company was formerly known as Rackspace.com, Inc. and changed its name to Rackspace Hosting, Inc. in June 2008. Rackspace Hosting, Inc. was founded in 1998 and is headquartered in San Antonio, Texas.
- [By Monica Gerson]
Rackspace Hosting, Inc. (NYSE: RAX) reported better-than-expected earnings for the first quarter, but the company missed analysts’ sales estimates. Rackspace shares dropped 7.72 percent to $20.80 in the after-hours trading session.
Top 10 Safest Stocks For 2017: TESARO, Inc.(TSRO)
TESARO, Inc., an oncology-focused biopharmaceutical company, identifies, acquires, develops, and commercializes cancer therapeutics and oncology supportive care products in the United States and internationally. Its product portfolio consist of Rolapitant, a neurokinin-1 receptor antagonist, which has completed phase 3 oral formulation trials, as well as is in phase 1 intravenous clinical trials for the prevention of chemotherapy induced nausea and vomiting; Niraparib, an orally active and potent poly polymerase inhibitor that is in phase 3 clinical trials to treat ovarian cancer; and TSR-011, an orally available anaplastic lymphoma kinase inhibitor, which is in phase 1/2a dose escalation clinical trial in cancer patients. The company also offers KEYTRUDA, a programmed cell death protein 1 antibody for the treatment of certain melanomas. TESARO, Inc. was founded in 2010 and is headquartered in Waltham, Massachusetts.
- [By Ben Levisohn]
Guggenheim’s Tony Butler and Kaitlin Sandor argue that Gilead Sciences (GILD) should buy Syndax Pharmaceuticals (SNDX), Corvus Pharmaceuticals (CRVS), and Tesaro (TSRO) to solve its problem of slowing sales:
- [By Ben Levisohn]
Who has PARP? A poly ADP-ribose polymerase inhibitor (PARPi) kills cancer cells by interfering tumor DNA repair pathway with the potential to treat ovarian, breast and prostate cancer. Studies have shown that patients with BRCA mutations (BRCAmut) respond to PARPi. AstraZenecas (AZN) PARPi was approved in 2014 whileClovis Oncology (CLVS) and Tesaro (TSRO) both have positive Phase III data. Clovis licensed its PARPi from Pfizer (PFE) in 2011 and Tesaro licensed its PARPi from Merck (MRK) in 2012, after Sanofis (SNY) PARPi (later demonstrated that it cannot block PARP) failed in Phase III in early 2011.
Top 10 Safest Stocks For 2017: National Steel Corporation(SID)
Companhia Siderurgica Nacional primarily operates as an integrated steel producer in Brazil and Latin America. The company principally produces carbon steel and various steel products. Its products include slabs, which are semi-finished products used for processing hot-rolled, cold-rolled, or coated coils and sheet products; hot-rolled products that comprise heavy-gauge hot-rolled coils and sheets, and light-gauge hot-rolled coils and sheets; cold-rolled products, including cold-rolled coils and sheets; and galvanized products consisting of flat-rolled steel coated with zinc or a zinc-based alloy. The company also offers tin mill products, which consist of flat-rolled low-carbon steel coils or sheets, such as tin plate, tin free steel,low tin coated steel, and black plate products. In addition, it engages in mining business by owning iron ore, limestone, dolomite, and tin mines comprising the Namisa property, Casa de Pedra mine, Arcos mine, and Santa Barbara mine; and invo lves in logistics business that includes railway and port facilities. Further, the company produces and sells cement; and engages in the generation of power plants. It sells its steel products as a raw material for various manufacturing industries, including the automotive, home appliance, packaging, construction, and steel processing industries. The company offers its products to customers directly through its sales force, as well as through distributors for subsequent resale. It also exports its products to Europe, Latin America, Asia, and North America. Companhia Siderurgica Nacional was founded in 1941 and is headquartered in Sao Paulo, Brazil.
- [By Lisa Levin]
In trading on Thursday, basic materials shares fell by 0.45 percent. Meanwhile, top losers in the sector included Companhia Siderurgica Nacional (ADR) (NYSE: SID), down 13 percent, and Dominion Diamond Corp (NYSE: DDC), down 9 percent.
Top 10 Safest Stocks For 2017: Aethlon Medical, Inc.(AEMD)
Aethlon Medical, Inc., incorporated on April 17, 1991, is a medical device company, which creates medical devices to address unmet therapeutic needs in infectious disease, cancer and other life-threatening conditions. The Company’s lead product is the Aethlon Hemopurifier, which is a device that selectively targets the elimination of circulating viruses and tumor-secreted exosomes that promote cancer progression. The Aethlon Hemopurifier sheds glycoproteins to treat infectious viral pathogens. In oncology indications, the Hemopurifier targets the removal of circulating exosomes, which are secreted by tumors to prevent the immune system from rejecting the tumors. Through its majority-owned subsidiary, Exosome Sciences, Inc. (Exosome), the Company is also developing exosome-based products to diagnose and monitor neurological disorders and cancer.
In addition, the Company operates under a Department of Defense contract through the Defense Advanced Research Projec ts Agency (DARPA), related to the development of a sepsis treatment device. The Company also operates under a second Department of Defense contract as a subcontractor. Under these contracts, the Company’s tasks include the development of a dialysis-like device to prevent sepsis, a fatal bloodstream infection. The Company is also studying the use of its Hemopurifier as a therapeutic solution against viral pathogens that are not treatable with antiviral drugs, as well as viral pathogens that have evolved to become drug resistant.
The Aethlon Hemopurifier addresses antiviral drug-resistance in Hepatitis C virus and Human Immunodeficiency Virus-infected individuals and serves as a countermeasure against viral pathogens not addressed by drug or vaccine therapies. In the Company’s clinical studies that are conducted in India, safety and efficacy observations of Hemopurifier therapy have been observed in both Hepatitis C virus and Human Immunodeficiency Virus-infected individuals. Delivery of Hemopurifier therapy can occur thro! ugh the infrastructure of continuous renal replacement therapy and dialysis instruments routinely found in hospitals and clinics. The Hemopurifier is designed to provide a spectrum mechanism to inhibit the presence of certain cancer and infectious disease related particles. Treatment with the Hempurifier lasts from three to six and one half hours in duration. The Company has conducted Hepatitis C virus treatment studies for Aethlon Hemopurifier.
In addition to treating Hepatitis C virus-infected individuals, the Company has conducted a single proof-of-principle treatment study related to the treatment of Human Immunodeficiency Virus. In the study, Hemopurifier therapy reduced viral load by around 93% in a Human Immunodeficiency Virus-Acquired Immunodeficiency Syndrome-infected individual without the administration of antiviral drug therapy.
The Company competes with Asahi Kasei Kurary Medical.
- [By Monica Gerson]
General Mills, Inc. (NYSE: GIS) is expected to report its quarterly earnings at $0.60 per share on revenue of $3.86 billion. Pier 1 Imports Inc (NYSE: PIR) is projected to post a quarterly loss at $0.05 per share on revenue of $420.05 million. Acuity Brands, Inc. (NYSE: AYI) is estimated to report its quarterly earnings at $2.03 per share on revenue of $847.79 million. Monsanto Company (NYSE: MON) is projected to report its quarterly earnings at $2.40 per share on revenue of $4.49 billion. Worthington Industries, Inc. (NYSE: WOR) is expected to report its quarterly earnings at $0.64 per share on revenue of $692.48 million. Progress Software Corporation (NASDAQ: PRGS) is projected to post its quarterly earnings at $0.29 per share on revenue of $94.64 million. UniFirst Corp (NYSE: UNF) is estimated to report its quarterly earnings at $1.34 per share on revenue of $366.28 million. Exfo Inc (NASDAQ: EXFO) is expected to post its quarterly earnings at $0.06 per share on revenue of $60.87 million. OMNOVA Solutions Inc. (NYSE: OMN) is projected to report its quarterly earnings at $0.14 per share on revenue of $205.40 million. 8Point3 Energy Partners LP (NASDAQ: CAFD) is estimated to post a quarterly loss at $0.01 per share on revenue of $11.60 million. Park Electrochemical Corp. (NYSE: PKE) is expected to report its quarterly earnings at $0.22 per share on revenue of $35.30 million. Xplore Technologies Corp. (NASDAQ: XPLR) is projected to post its quarterly earnings at $0.01 per share on revenue of $24.00 million. Investors Real Estate Trust (NYSE: IRET) is expected to post its quarterly earnings at $0.14 per share on revenue of $56.87 million. Tel-Instrument Electronics Corp. (NYSE: TIK) is estimated to post earnings for the latest quarter. Aethlon Medical, Inc. (NASDAQ: AEMD) is expected to post a quarterly loss at $0.20 per share. Ossen Innovation Co Ltd (ADR) (NASDAQ: OSN) is projected to post ea
Top 10 Safest Stocks For 2017: Extra Space Storage Inc(EXR)
Extra Space Storage, Inc. operates as a real estate investment trust (REIT) in the United States. It engages in property management and development activities that include acquiring, managing, developing, and selling, as well as the rental of self-storage facilities. As of December 31, 2006, Extra Space Storage owned interests in 567 properties located in 32 states and Washington, D.C., as well as managed 74 properties owned by franchisees or third parties. As a REIT, the company would not be subject to federal corporate income taxes if it distributes at least 90% of its taxable income to its stockholders. The company was founded in 1977 and is based in Salt Lake City, Utah.
- [By Shauna O’Brien]
On Tuesday, Goldman Sachs announced that it has removed Extra Space Storage, Inc. (EXR) from its Conviction Buy List.
The firm has maintained a “Buy” rating on EXR, and has lowered the company’s price target from $51 to $50. This price target suggests a 12% upside from the stock’s current price of $43.94.
Analyst Andrew Rosivach commented: “We think the stock is inexpensive on forward 2018E AFFO, but the higher 2014E multiple may require the stock to consolidate.”
Extra Space Storage shares were down 21 cents, or 0.47%, during Tuesday morning trading. The stock is up 21% YTD.
Top 10 Safest Stocks For 2017: Enbridge Inc(ENB)
Enbridge Inc. operates as an energy transportation and distribution company in the United States and Canada. Its Liquids Pipelines segment operates common carrier and contract crude oil, natural gas liquids (NGL), and refined products pipelines and terminals. The companys Gas Distribution segment operates as a natural gas utility that serves residential, commercial, and industrial customers in Central and Eastern Ontario, and Northern New York State, as well as in Quebec and New Brunswick. Its Gas Pipelines, Processing and Energy Services segment has interests in natural gas pipelines, including the Vector Pipeline and transmission and gathering pipelines in the Gulf of Mexico, as well as holds an interest in Aux Sable, a natural gas fractionation and extraction facility. This segment is also involved in the renewable energy projects, such as wind, solar, and geothermal projects with a generating capacity of approximately 2, 800 MW. The companys Sponsored Investments segment is involved in renewable and alternative power generation; crude oil and liquid petroleum transportation and storage; and natural gas and NGL gathering, treating, processing, and transportation. Enbridge Inc. has a strategic partnership with EDF Group for the development, construction, and operation of three French offshore wind farms. The company was formerly known as IPL Energy Inc. and changed its name to Enbridge Inc. in October 1998. Enbridge Inc. was founded in 1949 and is headquartered in Calgary, Canada.
- [By Callum Turcan]
Bridging the way
Enbridge (NYSE: ENB ) currently carries 2.2 million barrels of crude oil and liquidseach day through its vast 15,372 thousand mile pipeline system.Enbridge has recently undergonea $6.2 billion program to grow shipping capacity in Western Canada and the Bakken by 400,000 bpd. Western Canada is home to the booming oil sands play, so Enbridge is trying to capitalize on two high-growth markets.
Top 10 Safest Stocks For 2017: Gilead Sciences, Inc.(GILD)
Gilead Sciences, Inc., a research-based biopharmaceutical company, discovers, develops, and commercializes medicines in areas of unmet medical needs in North America, South America, Europe, and the Asia-Pacific. The companys products include Genvoya, Stribild, Complera/Eviplera, Atripla, Truvada, Viread, Emtriva, Tybost, and Vitekta for the treatment of human immunodeficiency virus (HIV) infection in adults; and Harvoni, Sovaldi, Viread, and Hepsera products for the treatment of liver diseases. It also offers Zydelig, a PI3K delta inhibitor, in combination with rituximab, for the treatment of certain blood cancers; Letairis, an endothelin receptor antagonist for the treatment of pulmonary arterial hypertension; Ranexa, a tablet used for the treatment of chronic angina; Lexiscan/Rapiscan injection for use as a pharmacologic stress agent in radionuclide myocardial perfusion imaging; Cayston, an inhaled antibiotic for the treat ment of respiratory systems in cystic fibrosis patients; and Tamiflu, an oral antiviral capsule for the treatment and prevention of influenza A and B. In addition, the company provides other products, such as AmBisome, an antifungal agent to treat serious invasive fungal infections; and Macugen, an anti-angiogenic oligonucleotide to treat neovascular age-related macular degeneration. Further, it has product candidates in various stages of development for the treatment of HIV/AIDS and liver diseases, such as hepatitis B virus and hepatitis C virus; inflammation/oncology; serious cardiovascular; and respiratory conditions, as well as diabetic nephropathy and ebola. The company markets its products through its commercial teams and/or in conjunction with third-party distributors and corporate partners. Gilead Sciences, Inc. has collaboration agreements with Bristol-Myers Squibb Company, Janssen R&D Ireland, Japan Tobacco Inc., and Galapagos NV. The company was founded in 1987 an d is headquartered in Foster City, California.
- [By Ben Levisohn]
Citigroup’s Robyn Karnauskas and Mohit Bansal wonder if Gilead Sciences’ (GILD) decision to limit its stock buybacks in the months ahead is a sign that it’s ready to engage in M&A:
Gilead CEO John Milligan Victor J. Blue/Bloomberg News
GileadCEO, at a broker conference last week, noted that the share buybacks for the reminder of the year will be at a much lesser rate then seen previously. The company thinks that they should now be more focused on broadening the pipeline than other activities. The co also noted that besides pipeline, another reason is offshore cash as the co generates 70% of the operating cash offshore while buybacks need to be done using onshore cash. Overall this strategic change, coupled with previous comments regarding the M&A, could be a signal that the company may become more active in the deal space.
Long term the co will continue returning cash to shareholders: The Company noted that for rest of the year the buybacks will slow down as the company shifts focus to broadening the pipeline. The co also noted that this does not mean they will not do buyback in long term as the company believes in the philosophy of returning cash to shareholders. The co still has $12B remaining in the buyback plan. The company continues to remain committed to growing dividend as well. We note that company has been aggressively buying back shares and did buyback $8B worth of shares in 1Q16 and $14B (shares plus warrants) in 2015.
The #1 question we are getting is what canGilead buy: We note that in a recent interview, the CEO has noted interest in oncology, liver and inflammation space. The CEO also noted urgency which bodes well with the recent decision to slow-down on the buyback front. Acc. to the CEO for him the most important thing is cutting edge technology which could make a difference five years from now.
Shares of Gilead Sciences have gained 0.2% to $86.40 at 2:43 p.m. today, lagging
- [By Ben Levisohn]
The biopharma team at Leerink has prescription data for Gilead Sciences’ (GILD) hepatitis-C treatments for the week ended Aug. 5. While the data continues to show downward pressure on Gilead’s franchise, its newest drug, Epclusa, is showing big gains:
Eric Risberg/Associated Press
Harvoni (GILD) scripts were up w/w, while Sovaldi (GILD) prescriptions were down w/w.
Harvoni TRx for the week were 4,693 (1,849 were NRx), representing a 0.6% increase in TRx and a 5.1% decrease in NRx w/w, after a 4.9% decrease in TRx and a 0.6% increase in NRx last week. Sovaldi TRx for the week were 1,267 (332 were NRx), representing a 3.1% decrease in TRx and a 2.4% decrease in NRx w/w, after an 8.5% decrease in TRx and a 10.8% decrease in NRx last week.
Epclusa (GILD) prescriptions increased w/w.
TRx for the week were 665 (537 were NRx), representing a 45.5% increase in TRx and a 27.6% increase in NRx w/w, after a 32.8% increase in TRx and a 24.6% increase in NRx last week. Epclusa is still in the early phase of its launch and it is not clear if IMS TRx data reflect total demand.
Gilead Sciences has ticked up 0.1% to $79.63 at 3:13 p.m. today, while the iShares Nasdaq Biotechnology ETF (IBB) has advanced 0.3% to $292.72.
- [By Ben Levisohn]
Gilead Sciences’ (GILD) 7x P/E plus potential to engineer some form of EPS CAGR seems to resonate strongly with investors despite lingering questions on the HCV franchise and underwhelming pipeline, but the HIV franchise and Genvoya launch appear to be in good shape with potential to finally drive the kind of earnings beats that can drive shares higher in our view.
- [By Ben Levisohn]
BMO Capital Markets analyst M. IanSomaiya and team take a look at the “clinical readouts through the end of 2016″ and find upside catalysts for Celgene (CELG), Amgen (AMGN), Biogen (BIIB), and Gilead Sciences (GILD) They explain:
Top 10 Safest Stocks For 2017: Computer Programs and Systems Inc.(CPSI)
Computer Programs and Systems, Inc., a healthcare information technology company, designs, develops, markets, installs, and supports computerized information technology systems to small and midsize hospitals in the United States. Its enterprise-wide system automates the management of clinical and financial data across the primary functional areas of a hospital. The company offers services that enable customers to outsource certain data-related business processes in the areas of clinical care, revenue cycle management, cost control, and regulatory compliance. Its software products include Patient Management, which enables a hospital to identify a patient at any point in the healthcare delivery system, and to collect and maintain patient information through the process of patient care; Financial Accounting that provides various business office applications to track and coordinate information needed for managerial decision-making; and Clinical, which automates record keeping and reporting for a range of clinical functions, such as laboratory, radiology, physical therapy, respiratory care, and pharmacy. The company?s software products also comprise Patient Care that allows hospitals to create computerized patient files; and Enterprise Applications, which provide software applications that support its products for use in various areas of the hospital. In addition, it offers support and maintenance services; business management services, including electronic billing, statement processing, accounts receivable management, payroll processing, contract management, and insurance services; and system implementation and training services, such as conversion and training. Further, the company sells computer hardware, peripherals, forms, and office supplies. It serves acute care community hospitals; and small specialty hospitals that focus on medical areas, such as surgery, rehabilitation, and psychiatry. The company was founded in 1979 and is headquartere d in Mobile, Alabama.
- [By Lisa Levin]
Shares of Computer Programs & Systems, Inc. (NASDAQ: CPSI) were down 31 percent to $27.00 after the company posted weaker-than-expected Q2 results.